Green J B, Green S, Alberts D S, O'Toole R, Surwit E A, Noltimier J W
Scott & White Clinic, Temple, Texas.
Obstet Gynecol. 1990 Apr;75(4):696-700.
A phase II study of the effectiveness and toxicity of carboplatin in the treatment of metastatic or locally advanced endometrial cancer was carried out by the Southwest Oncology Group. Thirty-two patients were registered in the study and 23 were fully evaluable for response and toxicity. Carboplatin was administered in a dose of 400 mg/m2 at 28-day intervals without concomitant hydration if blood counts had recovered sufficiently. There were seven responses (two complete and five partial responses) among the 23 evaluable patients, for an overall response rate of 30%. Four (two of two complete responders and two of five partial responders) of the seven responding patients remain alive at 839+ to 987+ days from the start of therapy. The two complete responders and one of the partial responders had small-volume disease, which may have contributed to their prolonged survival. Myelosuppression was the most prominent toxicity encountered. Seventeen of 27 patients evaluable for toxicity developed platelet counts of less than 75 X 10(3)/muL during therapy, but no hemorrhagic complications were encountered. Leukopenia was less prominent, with only nine of 27 patients developing white blood cell counts of less than 3.0 X 10(3)/microL. No important nephrotoxicity or neurotoxicity was observed. Emesis occurred in ten of 27 patients but was not dose-limiting. No unexpected toxicities were encountered. Carboplatin appears to be an active agent in the treatment of endometrial carcinoma.
西南肿瘤协作组开展了一项关于卡铂治疗转移性或局部晚期子宫内膜癌的有效性及毒性的II期研究。32名患者登记参与该研究，其中23名患者可对疗效和毒性进行全面评估。若血细胞计数已充分恢复，卡铂以400mg/m²的剂量每28天给药一次，无需同时进行水化治疗。在23名可评估患者中，有7例出现缓解（2例完全缓解和5例部分缓解），总缓解率为30%。从治疗开始起，7例缓解患者中有4例（2例完全缓解者中的2例以及5例部分缓解者中的2例）在839 +至987 +天仍存活。2例完全缓解者和1例部分缓解者疾病体积较小，这可能是其生存期延长的原因。骨髓抑制是最突出的毒性反应。在27例可评估毒性的患者中，17例在治疗期间血小板计数低于75×10³/μL，但未出现出血并发症。白细胞减少不那么突出，27例患者中只有9例白细胞计数低于3.0×10³/μL。未观察到重要的肾毒性或神经毒性。27例患者中有10例出现呕吐，但未达到剂量限制毒性。未出现意外的毒性反应。卡铂似乎是治疗子宫内膜癌的一种有效药物。
